TN2013000322A1 - Pharmaceutical compositions comprising human antibodies to pcsk9 - Google Patents

Pharmaceutical compositions comprising human antibodies to pcsk9

Info

Publication number
TN2013000322A1
TN2013000322A1 TNP2013000322A TN2013000322A TN2013000322A1 TN 2013000322 A1 TN2013000322 A1 TN 2013000322A1 TN P2013000322 A TNP2013000322 A TN P2013000322A TN 2013000322 A TN2013000322 A TN 2013000322A TN 2013000322 A1 TN2013000322 A1 TN 2013000322A1
Authority
TN
Tunisia
Prior art keywords
pcsk9
antigen
present
antibodies
binding fragments
Prior art date
Application number
TNP2013000322A
Other languages
French (fr)
Inventor
Corinne Hanotin
Laurence Bessac
Umesh Chaudhari
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2012/051321 external-priority patent/WO2012101253A1/en
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of TN2013000322A1 publication Critical patent/TN2013000322A1/en

Links

Abstract

The present invention relates to Pharmaceutical compositions comprising an antibody specifically binding to human proprotein convertase subtilisin/kexin type 9 (PCSK9), to methods for treating diseases or conditions in which proprotein convertase subtilisin/kexin type 9 (PCSK9) expression or activity causes an impact by administration of PCSK9-specific antibodies or antigen-binding fragments thereof and preferably by additional administration of an inhibitor of 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMG-CoA reductase). The present invention further relates to PCSK9-specific antibodies or antigen-binding fragments thereof for use in the treatment of diseases or conditions in which PCSK9 expression or activity causes an impact. The present invention also relates to articles of manufacture comprising packaging material, PCSK9-specific antibodies or antigen-binding fragments thereof, and a label or packaging insert indicating which groups of patients can be treated with said antibodies or fragments, which groups of patients must not be treated with said antibodies or fragments, and which dosage regimen should be used. The present invention further relates to methods of testing the efficacy of PCSK9-specific antibodies or antigen-binding fragments thereof for the treatment of certain diseases or conditions and for the treatment of specific sub-groups of patients.
TNP2013000322A 2011-11-08 2013-07-26 Pharmaceutical compositions comprising human antibodies to pcsk9 TN2013000322A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11306450 2011-11-08
PCT/EP2012/051321 WO2012101253A1 (en) 2011-01-28 2012-01-27 Pharmaceutical compositions comprising human antibodies to pcsk9

Publications (1)

Publication Number Publication Date
TN2013000322A1 true TN2013000322A1 (en) 2015-01-20

Family

ID=54337507

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2013000322A TN2013000322A1 (en) 2011-11-08 2013-07-26 Pharmaceutical compositions comprising human antibodies to pcsk9

Country Status (1)

Country Link
TN (1) TN2013000322A1 (en)

Similar Documents

Publication Publication Date Title
PH12021500018A1 (en) Human antibodies to pcsk9 for use in methods of treating particular groups of subjects
AR124482A2 (en) PHARMACEUTICAL COMPOSITIONS INCLUDING HUMAN ANTIBODIES AGAINST PCSK9
BR112014005799A2 (en) antibodies to pcsk9, their uses, and pharmaceutical composition
MY170089A (en) Methods for reducing lipoproten(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (pcsk9)
MX2016006226A (en) Dosing regimens for use with pcsk9 inhibitors.
MX2014001372A (en) Pharmaceutical composition for treatment and/or prevention of pancreatic cancer.
EA201490378A1 (en) TREATMENT OF MULTIPLE SCLEROSIS USING THE COMBINATION OF LACHINIMODA AND INTERFERON-β
NZ606988A (en) Combination pharmaceutical compositions and method of treatment of vertigo, kinetosis and vegetative-vascular dystonia
WO2015054619A3 (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
NZ702315A (en) Methods and uses for pro protein convertase subtilisin kexin 9 (pcsk9) inhibitors
EA201490653A1 (en) DERIVATIVES ESTRA-1,3,5 (10), 16-TETRAEN-3-CARBOXAMIDE, METHOD FOR THEIR PRODUCTION CONTAINING THEIR PHARMACEUTICAL PREPARATIONS
EA201400002A1 (en) METHODS TO TREAT DISEASES OF THE RETAIL
NZ606969A (en) A method of treating alzheimer’s disease
TN2013000322A1 (en) Pharmaceutical compositions comprising human antibodies to pcsk9
MX2013002503A (en) Combination of hdac inhibitors with thrombocytopenia drugs.
EA200801854A1 (en) NEW COMPOSITIONS
TH177074A (en) Antibody human antibodies against PCSK9 for use in the treatment of specific patient groups.
UA56025U (en) Method for determination of illegal drugs and drastic medicinal agents in human biological material
EA201201226A1 (en) SOLID MEDICINE FORM, possessing an anorexigenic action (OPTIONS)